The Experts below are selected from a list of 3492 Experts worldwide ranked by ideXlab platform

Neil J. Weissman - One of the best experts on this subject based on the ideXlab platform.

  • impact of post intervention minimal stent area on 9 month follow up patency of paclitaxel eluting stents an integrated intravascular ultrasound analysis from the taxus iv v and vi and taxus atlas workhorse long lesion and direct stent trials
    Jacc-cardiovascular Interventions, 2009
    Co-Authors: Akiko Maehara, Lazar Mandinov, Keith D Dawkins, Alan Yu, Eberhard Grube, Hong Wang, Neil J. Weissman
    Abstract:

    Objectives We investigated the predictive value of the intravascular ultrasound (IVUS) measured post-intervention minimum stent area (MSA) on 9-month follow-up paclitaxel-eluting stent (PES) patency compared with bare-metal stents (BMS). Background Stent underexpansion is a strong predictor for restenosis after sirolimus-eluting stent implantation, but the implication of underexpansion in PES is still unknown. Methods From the combined TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent trials, 1,580 patients (PES 1,098, BMS 482) in IVUS substudies were analyzed. The MSA that best predicted angiographic in-stent restenosis (ISR) (% diameter stenosis ≥50%) was determined. Results The post-intervention IVUS MSA was similar in PES and BMS (6.6 ± 2.5 mm2 vs. 6.7 ± 2.3 mm2, p = 0.92). At 9-month follow-up, ISR was lower in the PES group versus the BMS group (10% vs. 31%, p < 0.0001). Using multivariable logistic regression analysis, post-intervention IVUS MSA was the independent predictor of subsequent ISR in both the PES and BMS groups (p = 0.0002 for PES and p = 0.0002 for BMS). The ability of the post-intervention IVUS MSA to predict ISR was further assessed using receiver operating characteristic analysis. The post-intervention IVUS MSA was found to be a faithful discriminator between patients with and without ISR in both PES (c = 0.6382) and BMS (c = 0.6373). Finally, the optimal thresholds of post-intervention IVUS MSA that best predicted stent patency at 9 months were 5.7 mm2 for PES and 6.4 mm2 for BMS. Conclusions Post-intervention MSA measured by IVUS can predict 9-month follow-up stent patency after both PES and BMS implantation. (Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions; NCT00301522) (Direct Stenting of TAXUS Liberte-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions; NCT00371423) (A Study of the TAXUS Liberte Stent for the Treatment of Long De Novo Coronary Artery Lesions; NCT00371475) (A Study of the TAXUS Liberte Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels; NCT00371748)

Carlos Chaccour - One of the best experts on this subject based on the ideXlab platform.

  • targeting cattle for malaria elimination marked reduction of anopheles arabiensis survival for over six months using a Slow Release ivermectin implant Formulation
    Parasites & Vectors, 2018
    Co-Authors: Fredros O Okumu, Carlos Chaccour, Kija R Nghabi, Gloria Abizanda, Angel Irigoyen Barrio, Azucena Aldaz
    Abstract:

    Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. A Slow-Release Formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. This implantable ivermectin Formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting Formulation, which would be impractical or unacceptable for mass treatment of human populations.

  • Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a Slow-Release ivermectin implant Formulation
    'Springer Science and Business Media LLC', 2018
    Co-Authors: Carlos Chaccour, Fredros O Okumu, Gloria Abizanda, Angel Irigoyen Barrio, Azucena Aldaz, Kija Ngha’bi, Hannah Slater, Jose Luis Del Pozo, Gerry Killeen
    Abstract:

    Abstract Background Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. Results A Slow-Release Formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. Conclusions This implantable ivermectin Formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting Formulation, which would be impractical or unacceptable for mass treatment of human populations

Fredros O Okumu - One of the best experts on this subject based on the ideXlab platform.

  • targeting cattle for malaria elimination marked reduction of anopheles arabiensis survival for over six months using a Slow Release ivermectin implant Formulation
    Parasites & Vectors, 2018
    Co-Authors: Fredros O Okumu, Carlos Chaccour, Kija R Nghabi, Gloria Abizanda, Angel Irigoyen Barrio, Azucena Aldaz
    Abstract:

    Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. A Slow-Release Formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. This implantable ivermectin Formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting Formulation, which would be impractical or unacceptable for mass treatment of human populations.

  • Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a Slow-Release ivermectin implant Formulation
    'Springer Science and Business Media LLC', 2018
    Co-Authors: Carlos Chaccour, Fredros O Okumu, Gloria Abizanda, Angel Irigoyen Barrio, Azucena Aldaz, Kija Ngha’bi, Hannah Slater, Jose Luis Del Pozo, Gerry Killeen
    Abstract:

    Abstract Background Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. Results A Slow-Release Formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. Conclusions This implantable ivermectin Formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting Formulation, which would be impractical or unacceptable for mass treatment of human populations

Lazar Mandinov - One of the best experts on this subject based on the ideXlab platform.

  • long term impact of routinely detected early and late incomplete stent apposition an integrated intravascular ultrasound analysis of the taxus iv v and vi and taxus atlas workhorse long lesion and direct stent studies
    Jacc-cardiovascular Interventions, 2010
    Co-Authors: Daniel H. Steinberg, Steven G Ellis, Lazar Mandinov, Keith D Dawkins, Mark Turco, John A Ormiston, Alan Yu, Eberhard Grube, Gregg W Stone
    Abstract:

    Objectives We sought to determine the 2-year impact of early and late-acquired incomplete stent apposition (ISA) on clinical events. Background The late clinical impact of early or late-acquired ISA in bare-metal stents (BMS) and TAXUS stents (Boston Scientific, Natick, Massachusetts) is debatable. Methods We evaluated 1,580 patients enrolled in the intravascular ultrasound (IVUS) substudies of TAXUS IV, V, VI and TAXUS-ATLAS WH, LL, and DS trials. Results There were 96 cases of early ISA in 26 (7.2%) BMS patients, 35 (9.7%) TAXUS Express patients (p = 0.28 vs. BMS), and 35 (7.3%) TAXUS Liberte patients (p = 0.21 vs. TAXUS Express, and p = 1.00 vs. BMS). Major adverse cardiovascular events were similar at 9 months in patients with early ISA versus control subjects with no ISA for BMS (3.8% vs. 15.2%, p = 0.13) and for TAXUS (11.6% vs. 8.8%, p = 0.45). There was no impact of early ISA on stent thrombosis. At 9-month follow-up, there were 36 cases of late-acquired ISA in 7 (2.7%) BMS patients, 17 (3.1%) patients with TAXUS Slow-Release (TAXUS Express or TAXUS Liberte), and 12 (15.4%) patients receiving TAXUS moderate-Release. Over 2 ensuing years, major adverse cardiovascular events were similar in patients with late-acquired ISA versus control subjects with no ISA for BMS (14.3% vs. 7.9%, p = 0.54), TAXUS (overall, 8.3% vs. 8.1% p = 0.87), or TAXUS Slow-Release Formulation (0% vs. 7.9%, p = 0.28). There was no impact of late-acquired ISA on stent thrombosis. Conclusions Neither routinely detected acute ISA nor routinely detected late-acquired ISA in BMS or TAXUS patients was associated with adverse clinical events over long-term follow-up.

  • impact of post intervention minimal stent area on 9 month follow up patency of paclitaxel eluting stents an integrated intravascular ultrasound analysis from the taxus iv v and vi and taxus atlas workhorse long lesion and direct stent trials
    Jacc-cardiovascular Interventions, 2009
    Co-Authors: Akiko Maehara, Lazar Mandinov, Keith D Dawkins, Alan Yu, Eberhard Grube, Hong Wang, Neil J. Weissman
    Abstract:

    Objectives We investigated the predictive value of the intravascular ultrasound (IVUS) measured post-intervention minimum stent area (MSA) on 9-month follow-up paclitaxel-eluting stent (PES) patency compared with bare-metal stents (BMS). Background Stent underexpansion is a strong predictor for restenosis after sirolimus-eluting stent implantation, but the implication of underexpansion in PES is still unknown. Methods From the combined TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent trials, 1,580 patients (PES 1,098, BMS 482) in IVUS substudies were analyzed. The MSA that best predicted angiographic in-stent restenosis (ISR) (% diameter stenosis ≥50%) was determined. Results The post-intervention IVUS MSA was similar in PES and BMS (6.6 ± 2.5 mm2 vs. 6.7 ± 2.3 mm2, p = 0.92). At 9-month follow-up, ISR was lower in the PES group versus the BMS group (10% vs. 31%, p < 0.0001). Using multivariable logistic regression analysis, post-intervention IVUS MSA was the independent predictor of subsequent ISR in both the PES and BMS groups (p = 0.0002 for PES and p = 0.0002 for BMS). The ability of the post-intervention IVUS MSA to predict ISR was further assessed using receiver operating characteristic analysis. The post-intervention IVUS MSA was found to be a faithful discriminator between patients with and without ISR in both PES (c = 0.6382) and BMS (c = 0.6373). Finally, the optimal thresholds of post-intervention IVUS MSA that best predicted stent patency at 9 months were 5.7 mm2 for PES and 6.4 mm2 for BMS. Conclusions Post-intervention MSA measured by IVUS can predict 9-month follow-up stent patency after both PES and BMS implantation. (Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions; NCT00301522) (Direct Stenting of TAXUS Liberte-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions; NCT00371423) (A Study of the TAXUS Liberte Stent for the Treatment of Long De Novo Coronary Artery Lesions; NCT00371475) (A Study of the TAXUS Liberte Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels; NCT00371748)

Keith D Dawkins - One of the best experts on this subject based on the ideXlab platform.

  • long term impact of routinely detected early and late incomplete stent apposition an integrated intravascular ultrasound analysis of the taxus iv v and vi and taxus atlas workhorse long lesion and direct stent studies
    Jacc-cardiovascular Interventions, 2010
    Co-Authors: Daniel H. Steinberg, Steven G Ellis, Lazar Mandinov, Keith D Dawkins, Mark Turco, John A Ormiston, Alan Yu, Eberhard Grube, Gregg W Stone
    Abstract:

    Objectives We sought to determine the 2-year impact of early and late-acquired incomplete stent apposition (ISA) on clinical events. Background The late clinical impact of early or late-acquired ISA in bare-metal stents (BMS) and TAXUS stents (Boston Scientific, Natick, Massachusetts) is debatable. Methods We evaluated 1,580 patients enrolled in the intravascular ultrasound (IVUS) substudies of TAXUS IV, V, VI and TAXUS-ATLAS WH, LL, and DS trials. Results There were 96 cases of early ISA in 26 (7.2%) BMS patients, 35 (9.7%) TAXUS Express patients (p = 0.28 vs. BMS), and 35 (7.3%) TAXUS Liberte patients (p = 0.21 vs. TAXUS Express, and p = 1.00 vs. BMS). Major adverse cardiovascular events were similar at 9 months in patients with early ISA versus control subjects with no ISA for BMS (3.8% vs. 15.2%, p = 0.13) and for TAXUS (11.6% vs. 8.8%, p = 0.45). There was no impact of early ISA on stent thrombosis. At 9-month follow-up, there were 36 cases of late-acquired ISA in 7 (2.7%) BMS patients, 17 (3.1%) patients with TAXUS Slow-Release (TAXUS Express or TAXUS Liberte), and 12 (15.4%) patients receiving TAXUS moderate-Release. Over 2 ensuing years, major adverse cardiovascular events were similar in patients with late-acquired ISA versus control subjects with no ISA for BMS (14.3% vs. 7.9%, p = 0.54), TAXUS (overall, 8.3% vs. 8.1% p = 0.87), or TAXUS Slow-Release Formulation (0% vs. 7.9%, p = 0.28). There was no impact of late-acquired ISA on stent thrombosis. Conclusions Neither routinely detected acute ISA nor routinely detected late-acquired ISA in BMS or TAXUS patients was associated with adverse clinical events over long-term follow-up.

  • impact of post intervention minimal stent area on 9 month follow up patency of paclitaxel eluting stents an integrated intravascular ultrasound analysis from the taxus iv v and vi and taxus atlas workhorse long lesion and direct stent trials
    Jacc-cardiovascular Interventions, 2009
    Co-Authors: Akiko Maehara, Lazar Mandinov, Keith D Dawkins, Alan Yu, Eberhard Grube, Hong Wang, Neil J. Weissman
    Abstract:

    Objectives We investigated the predictive value of the intravascular ultrasound (IVUS) measured post-intervention minimum stent area (MSA) on 9-month follow-up paclitaxel-eluting stent (PES) patency compared with bare-metal stents (BMS). Background Stent underexpansion is a strong predictor for restenosis after sirolimus-eluting stent implantation, but the implication of underexpansion in PES is still unknown. Methods From the combined TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent trials, 1,580 patients (PES 1,098, BMS 482) in IVUS substudies were analyzed. The MSA that best predicted angiographic in-stent restenosis (ISR) (% diameter stenosis ≥50%) was determined. Results The post-intervention IVUS MSA was similar in PES and BMS (6.6 ± 2.5 mm2 vs. 6.7 ± 2.3 mm2, p = 0.92). At 9-month follow-up, ISR was lower in the PES group versus the BMS group (10% vs. 31%, p < 0.0001). Using multivariable logistic regression analysis, post-intervention IVUS MSA was the independent predictor of subsequent ISR in both the PES and BMS groups (p = 0.0002 for PES and p = 0.0002 for BMS). The ability of the post-intervention IVUS MSA to predict ISR was further assessed using receiver operating characteristic analysis. The post-intervention IVUS MSA was found to be a faithful discriminator between patients with and without ISR in both PES (c = 0.6382) and BMS (c = 0.6373). Finally, the optimal thresholds of post-intervention IVUS MSA that best predicted stent patency at 9 months were 5.7 mm2 for PES and 6.4 mm2 for BMS. Conclusions Post-intervention MSA measured by IVUS can predict 9-month follow-up stent patency after both PES and BMS implantation. (Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions; NCT00301522) (Direct Stenting of TAXUS Liberte-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions; NCT00371423) (A Study of the TAXUS Liberte Stent for the Treatment of Long De Novo Coronary Artery Lesions; NCT00371475) (A Study of the TAXUS Liberte Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels; NCT00371748)